Theralase Anti-Cancer Technology Validated at International Conference
24 4월 2014 - 7:59PM
Access Wire
TORONTO, ONTARIO / ACCESSWIRE / April 24, 2014 / Theralase
Technologies Inc. ("Theralase') (TSXV: TLT) (TLTFF: OTCBB)
announced today new research on its Photo Dynamic Compound (PDC)
technology, proven effective in the destruction of bacteria and
cancer, has been peer reviewed and approved for presentation at the
16th Annual Laser Optics International Conference to be held in
June 2014.
The new research scientifically proves that Theralase's patented
PDC technology can be activated by Near Infrared (NIR) laser light
destroying cancer cells that reside deep into tissue, providing a
higher kill rate in a single Photo Dynamic Therapy (PDT) treatment,
than previously possible, setting a new standard in the industry.
The scientific and medical community considers the research pivotal
because the Theralase PDCs are able to provide a solution to a
problematic issue in cancer treatment, the ability to destroy
cancerous tumours via PDT deep into tissue.
Cancer is a major worldwide disease, causing great threats to
human health. Tumour recurrence, metastasis (spread of cancer to
distant body parts) and drug resistance are making the disease
untreatable in many instances. There is therefore an urgent need to
develop technology that is effective in destroying cancer before it
has an opportunity to metastasize to distant body parts and render
the patient incurable. Providing a technology that is able to
eliminate ongoing cancer proliferation and destroy deep seated
tumours with a higher kill rate in a single PDT treatment is ground
breaking.
Dr. Arkady Mandel, Chief Scientific Officer of Theralase stated,
"Conventional cancer therapies, including chemotherapy and
radiation therapy, have many limitations such as toxic side
effects, drug resistance and the fact that they quite often fail to
completely destroy the tumour. PDT utilizes a class of minimally
invasive PDCs with many advantages such as an ability to administer
the treatment with minimal side effects, improved selectivity to
target only the cancer cells and virtually zero toxicity to the
body; however, light penetration is one of the major challenges in
PDT. Light in the UV to visible range (300 to 700 nm) has limited
tissue penetration depth restricting the therapeutic efficacy of
PDT for large or deep tumours for competitive PDCs. The NIR window
in the range of 700 to 970 nm, in which biological tissues have
minimal light absorption, is ideal for targeted cancer therapy.
Activation of the Theralase PDCs by NIR light now addresses this
issue. Therefore the results of our preclinical research are of
great scientific and potential clinical significance."
Roger Dumoulin-White, President and CEO of Theralase stated
that, "I am encouraged that the latest Theralase anti-cancer
research continues to receive such high accolades from the
international scientific and medical community. This validation of
our technology from some of the most well known experts in the
field supports the magnitude of our research and the fact that we
are breaking new ground in cancer research. By being able to target
cancer cells in deeper tissue than currently available allows
Theralase the ability to use our patented technology to target
cancer regardless of where it may lurk in the body."
About Theralase Technologies Inc.
Theralase Technologies Inc. designs, manufactures and markets
patented, superpulsed laser technology used in eliminating pain and
destroying cancer. Theralase technology is safe and effective in
eliminating pain, reducing inflammation and accelerating tissue
regeneration of numerous nerve, muscle and joint conditions.
Theralase is actively developing patented technology that is able
to target and destroy cancers, bacteria and viruses when light
activated.
Additional information is available at www.theralase.com and
www.sedar.com .
This press release contains forward-looking statements, which
reflect the Company's current expectations regarding future events.
The forward-looking statements involve risks and uncertainties.
Actual results could differ materially from those projected herein.
The Company disclaims any obligation to update these
forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchanges) accepts responsibility for the adequacy or
accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
Theralase Technologies Inc.
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com
Arkady Mandel
Chief Scientific Officer
Theralase Technologies Inc.
1.866.THE.LASE (843-5273) ext. 258
416.699.LASE (5273) ext. 258
amandel@theralase.com
www.theralase.com
SOURCE: Theralase Technologies Inc.
Theralase Technologies (TSXV:TLT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Theralase Technologies (TSXV:TLT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024